U.S. Judge Denies Amgen’s Request To Block Sale of Novartis’ Biosimilar of Neupogen
A federal judge has denied California-based Amgen's request to block the U.S. sale of Novartis AG's Zarxio, a biosimilar of Amgen's Neupogen. Amgen had argued that Novartis violated U.S. law on biosimilars by failing to provide Amgen with a copy of its FDA application and that Novartis must wait six months before it can market the drug. Amgen spokesperson Kristen Davis said the company intends to appeal the judge's decision.
- "Judge Denies Amgen's Request To Block Novartis' Biosimilar of Neupogen" (Loftus, Wall Street Journal, 3/19).
- "U.S. Judge Rejects Amgen Bid To Block 'Biosimilar' Neupogen" (Pierson, Reuters, 3/19).